Celularity Inc. Files 8-K: Other Event Reported

Ticker: CELUW · Form: 8-K · Filed: Nov 8, 2024 · CIK: 1752828

Sentiment: neutral

Topics: 8-K, other-event

Related Tickers: CELU

TL;DR

Celularity filed an 8-K for an 'Other Event' on Nov 8, 2024 - details TBD.

AI Summary

Celularity Inc. filed an 8-K on November 8, 2024, reporting an "Other Event." The filing does not contain specific details about the event, dollar amounts, or dates beyond the filing date itself. The company, previously known as GX Acquisition Corp., is incorporated in Delaware and operates in the Pharmaceutical Preparations industry.

Why It Matters

This filing indicates a material event has occurred for Celularity Inc., but the lack of detail requires further investigation to understand its implications.

Risk Assessment

Risk Level: medium — The 'Other Event' designation without further details suggests potential undisclosed material information that could impact the company's stock.

Key Players & Entities

FAQ

What specific event is Celularity Inc. reporting in this 8-K filing?

The filing designates the event as 'Other Events' and does not provide specific details within the provided text.

When was this 8-K filing submitted to the SEC?

The filing was submitted on November 8, 2024.

What was Celularity Inc.'s former name?

Celularity Inc.'s former name was GX Acquisition Corp.

In which state is Celularity Inc. incorporated?

Celularity Inc. is incorporated in Delaware.

What is Celularity Inc.'s primary business sector?

Celularity Inc. operates in the Pharmaceutical Preparations sector, with SIC code 2834.

Filing Stats: 690 words · 3 min read · ~2 pages · Grade level 13.7 · Accepted 2024-11-08 16:30:35

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CELULARITY INC. Date: November 8, 2024 By: /s/ Robert J. Hariri Robert J. Hariri, M.D., Ph.D. Chairman and CEO

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing